Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Document › Details

BetaGlue Technologies S.p.A.. (3/4/24). "Press Release: BetaGlue Secures €10m EIC Accelerator Award". Milan.

Region Region EU (European Union)
Organisations Organisation BetaGlue Technologies S.p.A.
  Today BetaGlue Therapeutics S.p.A.
  Group BetaGlue Therapeutics S.p.A.
  Organisation 2 EIC Fund (European Innovation Council Fund)
  Group EU (govt)
Products Product cancer drug
  Product 2 business development (state/region)
     


BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products in the field of loco-regional radiotherapy to treat solid tumour cancers called ‘BAT-90’, today announced that it has been successful in its application for a €10m EIC Accelerator award.

> The European Innovation Council (EIC) Accelerator program is the most competitive of its kind in Europe.

> For the November 2023 cut-off just 42 of 1,083 (~4%) applicants were successful.

> The application process includes a detailed written submission, and then if short-listed, face-to-face cross-examination by a highly experienced jury panel.

The €10m award consists of a €2.5m grant component and a €7.5m equity component. The capital will be used to further advance the clinical development of the BAT-90 platform in multiple solid tumour cancer indications.

“The rigorous EIC Accelerator review process involves a high degree of technical and commercial scrutiny. Our success is testament to the clinical and commercial impact potential of our platform technology, and moreover, to the world-class executive team that have made this tremendous accomplishment” said Dr Colin Story, CEO.


About BetaGlue Technologies S.p.A.

BetaGlue Technologies S.p.A is an Italian clinical-stage oncology company developing a novel radiotherapy platform technology for the localised and targeted treatment of unresectable solid tumours. BetaGlue enjoys the support of a global Scientific Advisory Board, as well as of leading national and international advisers, in the development of its products.

   
Record changed: 2024-12-23

Advertisement

Picture Berlin Partner Top News Aignostics Mayo Clinic Pathology 650x200px

More documents for BetaGlue Therapeutics S.p.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x300px




» top